Alan Dal Pra, MD, University of Miami Sylvester Cancer Center, Miami, FL, discusses results of the Phase III randomized SAKK 09/10 trial (NCT01272050) that assessed the use of genomic classifiers as prognostic and predictive biomarkers for prostate cancer. The Decipher genomic classifier was found to have value as a prognostic marker for prostate cancer patients treated with radiotherapy. Furthermore, PORTOS was found to have potential as a predictive biomarker for prostate cancer patients treated with radiotherapy. More investigation is needed to further validate these markers. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть